u/discount_math_dm

Weekly dosing again, half-life in the same neighbourhood as sema, so a step change takes about a month to reach steady state. Judging a new step at day five is judging noise.

sulphur burps are the signature complaint and they are not dangerous

SURMOUNT-1 landed around 21% at 72 weeks on the top arm

Vials and pens carry the same molecule; what differs is fill volume, device tolerance and whether you are doing your own arithmetic. Neither is inherently more accurate.

Sent a vial to Medutest out of curiosity. Result was 99.5% against a claimed 99.0%, which is the first independent number I had seen for this compound anywhere.

Escrow is not standard in this space. Wanting it is reasonable; expecting it as default is not.

Same read. The energy-expenditure mechanism is the interesting bit and it is not established in humans at scale.

small molecule, not a peptide, and that changes everything about it

Same view. If the intake asked you nothing, the intake was a formality and you should factor that in.

The thing nobody warned me about was how much of this is logistics — storing it, remembering it, the same day every week.

Agreed on the heart-rate reports. They are consistent enough across the threads to be worth noting, not enough to be a finding.

the label on a compounded vial is a legal document, read it

Small fix — that is the network fee, not a supplier charge. The distinction matters for the complaint you are making.

Disagree. You are comparing doses across a small molecule and a peptide, which is not a comparison of anything.

Agreed that quote expiry is ordinary. Rates move and a time-limited quote is not a pressure tactic on its own.

Correction: patient-specific refers to the prescription, not to a bespoke formulation. Common misreading and it changes the argument.

Agreed, and the trial number is a mean of a very wide distribution — the tails are enormous and nobody posts from the middle.

What the glucagon arm is doing, as best anyone can say from public data.

GLP-1 and GIP agonism cover appetite and insulin secretion in ways that are now reasonably well characterised. Glucagon receptor agonism is the third leg and it is associated with increased energy expenditure and with effects on hepatic fat.

Mechanistically that is why this compound reads as a different proposition rather than a stronger version of a dual agonist. Clinically, the size and durability of that difference in humans is precisely what is not yet established, and anyone telling you otherwise is filling a gap with confidence.

switching from sema is not a dose conversion, there is no clean equivalence

nothing containing this is approved anywhere and research material is not for human use

Agreed that phase 3 is where the comparison becomes fair. Everything before it is inference.

The one mistake that cannot be undone, and why it keeps happening.

The same token symbol exists on multiple chains. The wallet interface shows you the symbol prominently and the network in small type. Sending on the wrong chain to an address that looks perfectly valid usually means the funds are unrecoverable by either party.

The protection is procedural rather than technical: confirm the network in writing with the recipient before sending, verify the address format matches that network, and send a small test first. None of that requires understanding the chain — it requires treating the network field as the most important thing on the screen, which the interface design does not encourage.

Read the phase 2 paper twice before ordering anything. Recommend that to anyone in this board: the error bars are the interesting part.

16kg over 82 weeks, never went past 10mg, and injection-site soreness stayed mild the whole way. Posting because the loud threads are all 15mg.

the same token exists on several chains and they are not interchangeable

The transaction hash is the canonical receipt: it is public, verifiable by either party, and it is what a support query should quote.

Disagree. "More receptors means more effect" is not how any of this works and the trial data does not support the linear story.

What would the new rule do to the vendor evidence standard?

Compared milligram figures across two completely different molecule classes in a comment. Deserved the correction.

potency testing on the finished preparation is the thing to ask for

Small fix: SURMOUNT is the obesity programme, SURPASS is the type-2 programme. They are different endpoints and the numbers do not transfer.

How a rule actually changes here, since people assume it is arbitrary.

Disagreeing with this bit: making individual cases public by default is worse for the person being moderated.

On comparing yourself with the trial number.

Agreed, with one qualifier: that is the mean of the top arm and the spread around it was enormous.

Network fees are set by chain congestion at the time of sending. They are paid to the network, not to the recipient, and they vary by hour as well as by chain.

Confirmations are the count of blocks built on top of the one containing your transaction.

cesar_ivaturi is right about confirmations. "Sent" is not a status.

Which week did the appetite change actually land for you?

What breaks if we make that change?

This. Modmail first is not bureaucracy; it stops individual cases turning into a public pile-on.

Who does this help, and who does it cost?

Vials and pens carry the same molecule; what differs is fill volume, device tolerance and whether you are doing your own arithmetic. Neither is inherently more accurate.